Wed, Mar 4, 2015, 4:30 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

  • ugt_92251 ugt_92251 Aug 24, 2014 1:00 PM Flag

    You do understand NeuVax now easily confirms $Gale as a 200+ valuation

    The stock market has already bestowed that valuation upon our market space. By all means you need to include& expand your DD to compare $gale & $pbyi. This shows without any single individuals opinion how you should expect the market will one again within reason respond to interm blind data release of the 70th recurrence of NeuVax Phase 3 data. $gale longs are expecting a repeat of 78% of NeuVax treated patients to not
    experience a recurrence. I myself believe from the phase 2 results that with the booster that recurrence will be all inclusive in resulting in zero recurrences.... as was proven when included in the Phase 2 study. As many posting you will find on this board please take time to ask just this one question upon reading a posted message. Has the author of the post presented factual verifiable information, which is presented in a non forcefully
    manner without using vulgarities and invites the reader to ask questions either for or against successful trials?
    You must seek the truth in this investment... It,s your journey in life.... Peace in your investments

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.95+0.10(+5.41%)4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.